CLEC9A and neoplasm: Specifically, murine CD8a+CD103+BATF3+CLEC9A+XCR1+ cDC1s have been demonstrated to have a critical role in the cross-presentation of tumor antigens and are generally thought to be indispensable in the development of host anti-tumor immune responses (14–17).